scispace - formally typeset
R

Ruben C. Hartkoorn

Researcher at École Polytechnique Fédérale de Lausanne

Publications -  50
Citations -  2664

Ruben C. Hartkoorn is an academic researcher from École Polytechnique Fédérale de Lausanne. The author has contributed to research in topics: Mycobacterium tuberculosis & Chemistry. The author has an hindex of 25, co-authored 44 publications receiving 2195 citations. Previous affiliations of Ruben C. Hartkoorn include University of Geneva & Pasteur Institute.

Papers
More filters
Journal ArticleDOI

Cross-Resistance between Clofazimine and Bedaquiline through Upregulation of MmpL5 in Mycobacterium tuberculosis

TL;DR: In this paper, mutations in the transcriptional regulator Rv0678, with concomitant upregulation of the multisubstrate efflux pump, MmpL5, accounted for this cross-resistance.
Journal ArticleDOI

Towards a new combination therapy for tuberculosis with next generation benzothiazinones

TL;DR: Compared to BTZ043, PBTZ169 has improved potency, safety and efficacy in zebrafish and mouse models of tuberculosis (TB), and when combined with other TB drugs, it showed additive activity against M. tuberculosis in vitro except with bedaquiline (BDQ) where synergy was observed.
Journal ArticleDOI

Towards a new tuberculosis drug: pyridomycin - nature's isoniazid.

TL;DR: In this article, the NADH-dependent enoyl- (Acyl-Carrier-Protein) reductase InhA as the principal target and demonstrate that pyridomycin inhibits mycolic acid synthesis in M. tuberculosis.
Journal ArticleDOI

Virulence Regulator EspR of Mycobacterium tuberculosis Is a Nucleoid-Associated Protein

TL;DR: EspR is a novel nucleoid-associated protein, with both architectural and regulatory roles, that impacts cell wall functions and pathogenesis through multiple genes, and was shown to be growth phase-dependent, peaking in the stationary phase.
Journal ArticleDOI

Simple Model for Testing Drugs against Nonreplicating Mycobacterium tuberculosis

TL;DR: This model for testing drugs against nongrowing cells that exploits the 18b strain of M. tuberculosis 18b is proposed, a streptomycin (STR)-dependent mutant that retains significant metabolic activity in vitro, remaining positive in the resazurin reduction assay.